

Supplementary Table 1. Continued comparison of patients' baseline characteristics between the groups

Variables	PBT (n=20)	Tirofiban (n=35)	Tirofiban And Adenosine (n=25)	p*	p ^a	p ^β	p ^γ
Killip 1, n(%)	14 (66.6)	20 (57.1)	13 (53)	0.359			
Killip 2, n(%)	2 (9.5)	6 (17.1)	8 (32)				
Killip 3, n(%)	1 (4.7)	4 (11.4)	3 (12)				
Killip 4, n(%)	4 (19.0)	5 (14.2)	1 (4)				
In-Hospital Death, n(%)	6 (28.6)	4 (11.4)	1 (4)	0.047			
Contrast-Induced Nephropathy, n(%)	3 (14.2)	34 (8,5)	3 (12)	0.783			
EF, %	35 (26.25-47)	45 (35-55)	40(31.5-47.5)	0.194			
Creatinine, mg/dL	0.91(0.75-1.20)	0.91(0.83-1.06)	0.85(0.76-0.91)	0.152			
HbA1c, %	6.3(5.5-7.6)	6.1(5.7-7.5)	6.1(5.7-7.0)	0.998			
Total Cholesterol, mg/dL	170±45	190±41	194±39	0.119			
LDL, mg/dL	109±40	125±37	128±34	0.179			
Neutrophils, 10 ³ /mm ³	8.63±3.04	9.7±3.5	9.7±4.9	0.533			
Platelets, 10 ³ /mm ³	276±90	247±65	257±71	0.393			
Leukocytes, 10 ³ /mm ³	10.94(8.74-12.68)	12.8(9.24-13.8)	11.6(7.1-17.7)	0.305			
Hemoglobin, g/dL	13.3(11.85-15.0)	14.5 (13.2-15.3)	14.0 (12.8-14.9)	0.255			
Peak Troponin, ng/L	23504 (5423-25000)	25000 (16175-25000)	25000 (19107-25000)	0.299			
Triglyceride, mg/dL	85(71.5-95.5)	122 (91-190)	111(74-151.5)	0.024	0.007	0.1	0.261
HDL, mg/dL	41(36.5-44.5)	36(29-40)	39(31.5-48)	0.105			
Albumin, mg/L	39.5(35.5-41.7)	42(40-43)	41(38.5-43.5)	0.018	0.005	0.089	0.237

ACS: acute coronary syndrome; AF: atrial fibrillation; DM: diabetes mellitus; EF: ejection fraction; HDL: high-density lipoprotein; HT: hypertension; CAD: history of coronary arterial disease; LDL: low-density lipoprotein.

*p value between all groups

^ap value between PBT group and tirofiban group

^βp value between PBT group and tirofiban-adenosine group

^γp value between Tirofiban group and tirofiban-adenosine group

Supplementary Table 2. Comparison of patients' angiographic characteristics between the groups

Variables	PBT (n=20)	Tirofiban (n=35)	Tirofiban And Adenosine (n=25)	p*	p ^a	p ^β	p ^γ
Vascular diameter, mm	3.0(2.62-3.87)	3.0(3.0-3.0)	3.5(3.0-4.0)	0.053			
Stent Length, mm	36(24-47)	29(20-38)	24(20-32)	0.024	0.048	0.006	0.434
Target Vessel							
LAD, n (%)	2 (9.5)	9 (25.7)	12 (48.0)	0.001	0.003	0.001	0.231
CX, n (%)	11 (52.3)	4 (11.4)	1 (4.0)				
RCA, n (%)	3 (14.2)	16 (45.7)	7 (28.0)				
Safen, n (%)	5 (23.8)	6 (17.1)	5 (20.0)				
Pre-dilatation, n (%)	19 (90.4)	33 (94.2)	24 (96.0)	0.732			
Post-dilatation, n (%)	11(52.3)	24 (68.5)	12 (48.0)	0.234			
DAPT bolus							
Clopidogrel, n (%)	4 (19.0)	3 (8.5)	9 (36.0)	0.016	0.398	0.076	0.007
Ticagrelor, n (%)	17 (80.9)	31 (88.5)	13 (52.0)				
Prasugrel, n (%)	0 (0)	1 (2.8)	3 (12.0)				
DES, n (%)	20 (95.2)	28 (80.0)	19 (76.0)	0.195			
TIMI 0, n (%)	1 (4.7)	1 (2.8)	0 (0)	0.033	0.165	0.005	0.266
TIMI 1, n (%)	1 (4.7)	9 (25.7)	12 (48.0)				
TIMI 2, n (%)	10 (47)	17 (48.5)	10 (40.0)				
TIMI 3, n (%)	9 (42.8)	8 (22.8)	3 (12.0)				

CX: circumflex artery; LAD: left anterior descending artery; RCA: right coronary artery; TIMI, Thrombolysis in myocardial infarction.

*p value between all groups

^ap value between PBT group and tirofiban group

^βp value between PBT group and tirofiban-adenosine group

^γp value between Tirofiban group and tirofiban-adenosine group

Supplementary Table 3. Evaluation of parameters, predicting TIMI flow with single- and multi-variable logistic regression analysis.

Variables	Single-variable			Multi-variable		
	OR	95% CI	P value	OR	95% CI	P value
Age	1.050	1.000-1.103	0.051			
Gender	0.830	0.272-2.526	0.742			
Triglyceride	0.998	0.991-1.005	0.564			
Albumin	1.015	0.907-1.135	0.797			
Vascular diameter	0.181	0.050-0.648	0.009	0.227	0.066-0.781	0.019
Stent length	1.005	0.963-1.048	0.823			
Target vessel	0.965	0.610-1.528	0.880			
DAPT bolus	0.739	0.257-2.122	0.574			
Treatment administration route	0.421	0.203-0.875	0.020	0.482	0.219-1.061	0.070

DAPT: Dual Antiplatelet Therapy